TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$345 Million

Revolution Medicines, Inc.

Follow-on Offering

Bookrunner, March 2023

Revolution Medicines, Inc.

Revolution Medicines, Inc. (“Revolution Medicines” or the “Company”) is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. Revolution Medicines possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. The Company’s understanding of genetic drivers and adaptive resistance mechanisms in cancer, coupled with robust drug discovery and medicinal chemistry capabilities, has guided Revolution Medicines to establish a deep pipeline targeting critical signaling nodes within the RAS pathway and associated pathways. This cohesive approach underpins the Company’s clinical strategy of exploring mechanism-based dosing paradigms and in-pathway combinations to optimize treatment for cancer patients.